Tag: Feng Zhang

February 15, 2017

The CRISPR-Cas9 Patent Dispute

The US Patent Office has ruled “no interference in fact” on CRISPR-Cas9 Patent dispute.
February 5, 2017

5 Top NASDAQ Biotech Stocks: Zosano Pharma Up 160 Percent

Here's a closer look at last week's top gainers.
December 19, 2016

Editas Medicine Extends CRISPR Genome Editing Licensing

Editas Medicine, a leading genome editing company, today announced it has exclusively licensed intellectual property related to new CRISPR technologies...
March 10, 2016

After Hot IPO Editas Medicine Bogged Down by CRISPR/Cas9 Legal Issues

Editas Medicine's share price went on a tear following its IPO in February. In the last two days, however, it's...